Bihua Chen sold $47M of MLTX
other at MoonLake Immunotherapeutics. 6,499,978 shares at an average of $7.21, traded Sep 29, 2025, filed Oct 1, 2025.
Score components
- +8RoleOther
- +25Trade size$46.9M at market
- +20Share of holdings soldSold 77% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +43.1%, 3m +86.7%, 6m +134.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000929638-25-003712, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 29, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -70,748 | $9.38 | $664k | 8,423,403 | Oct 1, 2025 |
| Sep 29, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -232,460 | $8.40 | $2.0M | 8,190,943 | Oct 1, 2025 |
| Sep 29, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -3,390,943 | $7.58 | $26M | 4,800,000 | Oct 1, 2025 |
| Sep 29, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -2,800,000 | $6.61 | $19M | 2,000,000 | Oct 1, 2025 |
| Sep 30, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -5,827 | $6.96 | $41k | 1,994,173 | Oct 1, 2025 |
Related signals
Other insiders at MoonLake Immunotherapeutics and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $22k 1,100 shares | -0% | |
| 28Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $1.0M 52,448 shares | -2% | |
| 26Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $878k 43,700 shares | -2% | |
| 17Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $322k 16,105 shares | -1% | |
| 38Weak | MoonLake Immunotherapeutics | da Silva Jorge Santos Chief Executive Officer | $2.0M 102,225 shares | -4% | |
| 44Moderate | MoonLake Immunotherapeutics | da Silva Jorge Santos Chief Executive Officer | $957k 47,775 shares | -2% | |
| 40Moderate | MoonLake Immunotherapeutics | Matthias Bodenstedt Chief Financial Officer | $862k 39,120 shares | -3% | |
| 32Weak | MoonLake Immunotherapeutics | Matthias Bodenstedt Chief Financial Officer | $352k 17,876 shares | -2% | |
| 28Weak | MoonLake Immunotherapeutics | Kristian Reich Chief Scientific Officer | $2.9M 150,000 shares | -5% | |
| 15Weak | MoonLake Immunotherapeutics | Matthias Bodenstedt Chief Financial Officer | $273k 13,653 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.